Company Filing History:
Years Active: 2003-2007
Title: Jan G J Van De Winkel: Innovator in Monoclonal Antibodies
Introduction
Jan G J Van De Winkel is a notable inventor based in Odijk, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of two patents to his name, his work has implications for cancer treatment and infectious diseases.
Latest Patents
One of his latest patents is titled "Human monoclonal antibodies to FC alpha receptor (CD89)." This patent discloses human monoclonal antibodies that specifically bind to the Fc alpha receptor (CD89). These antibodies are designed to target human effector cells, such as macrophages, against various target cells, including cancer cells and infectious agents. The invention also includes the construction of bifunctional antibodies or heteroantibodies that combine the binding region from an anti-Fc-alpha receptor antibody with a target-specific antibody. This innovative approach allows targeted effector cells to specifically lyse target cells. Another significant patent is "Cyanidin compositions and therapeutic and diagnostic uses therefor." This patent provides compositions comprising cyanidin reagents for binding to FcγRI receptors, along with methods and kits for their use.
Career Highlights
Jan G J Van De Winkel is associated with Medarex Inc., a company known for its advancements in monoclonal antibody technology. His work at Medarex has positioned him as a key figure in the biotechnology sector, contributing to the development of therapies that leverage the immune system to combat diseases.
Collaborations
Throughout his career, Jan has collaborated with notable colleagues, including Debra Hudson and Marcus A Van Dijk. These collaborations have further enhanced the research and development efforts in the field of monoclonal antibodies.
Conclusion
Jan G J Van De Winkel's contributions to the field of biotechnology, particularly in monoclonal antibodies, have the potential to revolutionize treatment options for various diseases. His innovative patents and work at Medarex Inc. underscore his importance as an inventor in this critical area of research.